Metrikler
Yayın
307
Açık Erişim
55
BM Sürdürülebilir Kalkınma Amaçları
Eğitim Bilgileri
2002 - 2006
2002 - 2006Tıpta Yandal Uzmanlık
Hacettepe Üniversitesi, İç Hastalıkları Abd, Tıbbi Onkoloji Bilim Dalı, Türkiye
2002 - 2006
2002 - 2006Tıpta Yandal Uzmanlık
Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı- Medikal Onkoloji Bilim Dalı, Türkiye
1997 - 2002
1997 - 2002Tıpta Uzmanlık
Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Türkiye
1997 - 2002
1997 - 2002Tıpta Uzmanlık
Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları Abd, Türkiye
1990 - 1997
1990 - 1997Doktora
Hacettepe Üniversitesi, Tıp Fakültesi, Türkiye
Araştırma Alanları
Tıp
Sağlık Bilimleri
Dahili Tıp Bilimleri
İç Hastalıkları
Onkoloji
Akademik Faaliyetlere Dayalı Araştırma Alanları
Avesis Araştırma Alanları
WoS Araştırma Alanları
Scopus Araştırma Alanları
Akademik Ünvanlar / Görevler
2014 - Devam Ediyor
2014 - Devam EdiyorProf. Dr.
Hacettepe Üniversitesi, Kanser Enstitüsü, Klinik Onkoloji Anabilim Dalı
2012 - 2014
2012 - 2014Doç. Dr.
Hacettepe Üniversitesi, Kanser Enstitüsü
2006 - 2010
2006 - 2010Öğretim Görevlisi
Hacettepe Üniversitesi, Kanser Enstitüsü
Yönetimsel Görevler
2013 - 2016
2013 - 2016Enstitü Müdür Yardımcısı
Hacettepe Üniversitesi, Kanser Enstitüsü
2013 - 2014
2013 - 2014Bölüm Başkan Yardımcısı
Hacettepe Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
Akademi Dışı Deneyim
2010 - 2012
2010 - 2012Doç. Dr.
SAĞLIK BAKANLIĞI, Doç. Dr.
Makaleler
Tümü (86)
SCI-E, SSCI, AHCI (73)
SCI-E, SSCI, AHCI, ESCI (79)
ESCI (5)
Scopus (76)
TRDizin (12)
2025
20251. Predictors of Chemotherapy Induced Neutropenia in Patients with Breast Cancer
Sari A., AKSOY S., Ascioglu S.
Journal of oncological sciences
, cilt.11, sa.2, ss.89-95, 2025 (Scopus, TRDizin)
2025
20252. Bone-modifying agents and survival in patients treated with immune checkpoint inhibitors
BAŞ O., GÜNER N. İ., Tokatlı M., GÜDÜK N., ŞAHİN T. K., YALÇIN N., et al.
Journal of medicine and palliative care (Online) , cilt.6, 2025 (TRDizin)
2025
20253. Gastrointestinal sistem maligniteli hastalarda demir eksikliği ve kronik hastalık anemisi ayırıcı tanısında soluble transferrin reseptör düzeylerinin yeri
Perkin P., Zeynelgil E., BAKIR F., Civelek B., AKSOY S., Abaylı E.
Turkish Journal of Clinics and Laboratory
, cilt.16, sa.2, ss.294-301, 2025 (TRDizin)
2025
20254. Fibrosis- 4 index and survival in early breast cancer patients
Bas O., TOKATLI M., GÜDÜK N., Karahan L., Sahin T. K., AKSOY S.
Acta Medica
, cilt.56, sa.2, ss.70-75, 2025 (TRDizin)
2025
20255. Does Adding Chemotherapy to Radiotherapy Improve Outcomes in Stage II Nasopharyngeal Carcinoma?
KAHVECIOĞLU A., YILMAZ M. T., MOHAMMADIPOUR S., SARI S. Y., CENGİZ M., GÜLLÜ İ., et al.
Türk Onkoloji Dergisi
, cilt.40, sa.2, ss.112-119, 2025 (ESCI, Scopus, TRDizin)
2025
20256. Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitors
ŞAHİN T. K., AKSOY S., GÜVEN D. C.
EXPERT REVIEW OF ANTICANCER THERAPY
, sa.5, ss.471-484, 2025 (SCI-Expanded)
2025
20257. Breast Radiotherapy: A Potential Risk Factor for Resistant Clone Development in Patients with Brain Metastasis
Yildirim H. c., Kavgacı G., Evlendi Y., CHALABIYEV E., Guven D. C., Dizdar O., et al.
Journal of oncological sciences
, cilt.11, sa.1, ss.7-13, 2025 (TRDizin)
2025
20258. The association between blood sodium levels and survival in patients treated with immune checkpoint inhibitors
ŞAHİN T. K., GÜVEN D. C., Durukan M., KAVGACI G., KAYGUSUZ Y., ARIK Z., et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
, sa.4, ss.129-137, 2025 (SCI-Expanded)
2025
20259. Modified cachexia index and survival in metastatic breast cancer patients treated with CDK 4-6 inhibitors
BAŞ O., Tokatli M., Savkliyildiz M., Yazarkan Y., Guduk N., Kilinc C., et al.
EXPERT REVIEW OF ANTICANCER THERAPY
, sa.4, ss.405-409, 2025 (SCI-Expanded)
2025
202510. Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer
Sahin T. K., Rizzo A., GÜVEN D. C., AKSOY S.
CANCER TREATMENT REVIEWS
, 2025 (SCI-Expanded, Scopus)
2025
202511. Clinical Characteristics and Management of Patients Admitted to the Supportive Care Clinic and Predisposing Factors of Unplanned Hospital Readmission: Single-Center Experience
BAŞ O., Tokatli M., Guduk N., Erdogan D., Boyraz N. E., Cengelci C., et al.
JOURNAL OF CLINICAL MEDICINE
, sa.8, 2025 (SCI-Expanded, Scopus)
2025
202512. Serum Albumin-Creatinine Ratio and Anthracycline Cardiotoxicity in Patients with Cancer
BAŞ O., Guduk N., Tokatli M., Guven D. C., ÖZER N., ŞENER Y. Z., et al.
JOURNAL OF CLINICAL MEDICINE
, sa.5, 2025 (SCI-Expanded, Scopus)
2025
202513. The perspectives and knowledge of patients with cancer on mpox and mpox vaccination: a cross-sectional study
ŞAHİN T. K., KAYGUSUZ Y., Icli M. C., AKSOY S., GÜVEN D. C.
CURRENT MEDICAL RESEARCH AND OPINION
, sa.1, ss.83-91, 2025 (SCI-Expanded, Scopus)
2025
202514. The association between HALP score and survival in patients treated with immune checkpoint inhibitors
ŞAHİN T. K., GÜVEN D. C., Durukan M., BAŞ O., KAYGUSUZ Y., ARIK Z., et al.
EXPERT REVIEW OF ANTICANCER THERAPY
, sa.1, ss.81-89, 2025 (SCI-Expanded)
2024
202415. Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancer
KAVGACI G., ŞAHİN T. K., Muderrisoglu T., Ileri S., GÜVEN D. C., AKSOY S.
EXPERT REVIEW OF ANTICANCER THERAPY
, sa.12, ss.1319-1326, 2024 (SCI-Expanded)
2024
202416. Ribociclib-induced autoimmune-like hepatitis: a case report
KAVGACI G., ŞAHİN T. K., SÖKMENSÜER C., BALABAN H. Y., AKSOY S.
JOURNAL OF CHEMOTHERAPY
, 2024 (SCI-Expanded, Scopus)
2024
202417. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)
AKYILDIZ A., GÜVEN D. C., KÖKSAL B., KARAOĞLAN B. B., Kivrak D., Ismayilov R., et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
, cilt.281, sa.9, ss.4991-4999, 2024 (SCI-Expanded, Scopus)
2024
202418. The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer
YILDIRIM H. Ç., Buyukkor M., KAVGACI G., ŞAHİN ÇELİK B., BİR YÜCEL K., DURSUN B., et al.
MEDICINE
, cilt.103, sa.30, 2024 (SCI-Expanded, Scopus)
2024
202419. Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study
Cho B. C., Brana I., Cirauqui B., AKSOY S., Couture F., Hong R., et al.
BMC CANCER
, cilt.23, sa.SUPPL 1, 2024 (SCI-Expanded, Scopus)
2024
202420. Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine
ŞAHİN T. K., AKYILDIZ A., DOĞAN O. T., KAVGACI G., GÜVEN D. C., AKSOY S.
PHARMACEUTICALS
, cilt.17, sa.7, 2024 (SCI-Expanded, Scopus)
2024
202421. Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors
KAVGACI G., GÜVEN D. C., KAYGUSUZ Y., KARACA E., DİZDAR Ö., Kilickap S., et al.
SUPPORTIVE CARE IN CANCER
, cilt.32, sa.7, 2024 (SCI-Expanded, Scopus)
2024
202422. Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER plus breast cancer
Saatci O., Alam R., Huynh-Dam K., Isik A., ÜNER M., BELDER N., et al.
CELL DEATH & DISEASE
, cilt.15, sa.6, 2024 (SCI-Expanded, Scopus)
2024
202423. Prognostic Significance of the Royal Marsden Hospital (RMH) Score in Patients with Cancer: A Systematic Review and Meta-Analysis
Sahin T. K., Rizzo A., AKSOY S., Guven D. C.
CANCERS
, cilt.16, sa.10, 2024 (SCI-Expanded, Scopus)
2024
202424. The Impact of Concurrent Chemotherapy on Stage II Nasopharyngeal Carcinoma
Yilmaz M. T., KAHVECİOĞLU A., Mohammadipour S., CENGİZ M., Gullu I., AKSOY S., et al.
RADIOTHERAPY AND ONCOLOGY
, 2024 (SCI-Expanded, Scopus)
2024
202425. Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer
Gedik M. E., Saatci O., Oberholtzer N., ÜNER M., Caliskan O. A., Cetin M., et al.
CANCER RESEARCH
, cilt.84, sa.9, ss.1475-1490, 2024 (SCI-Expanded, Scopus)
2024
202426. Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
Balmaña J., Fasching P. A., Couch F. J., Delaloge S., Labidi-Galy I., O’Shaughnessy J., et al.
Breast Cancer Research and Treatment
, cilt.204, sa.2, ss.237-248, 2024 (SCI-Expanded, Scopus)
2024
202427. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study
Yıldırım H. Ç., KUTLU Y., Mutlu E., Aykan M. B., Korkmaz M., Yalçın S., et al.
International Journal of Clinical Oncology
, cilt.29, sa.3, ss.258-265, 2024 (SCI-Expanded, Scopus)
2024
202428. Immunotherapy in the First-Line Treatment of Advanced Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis
GÜVEN D. C., Stephen B., ŞAHİN T. K., ÇAKIR İ. Y., AKSOY S.
Laryngoscope
, cilt.134, sa.1, ss.7-17, 2024 (SCI-Expanded, Scopus)
2024
202429. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
Machiels J., Tao Y., Licitra L., Burtness B., Tahara M., Rischin D., et al.
The Lancet Oncology
, 2024 (SCI-Expanded, Scopus)
2024
202430. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study
YILDIRIM H. Ç., Kapar C., KÖKSAL B., Seyyar M., Sanci P. C., Guliyev M., et al.
Journal of Chemotherapy
, 2024 (SCI-Expanded, Scopus)
2023
202331. Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer
Saatci O., Cetin M., ÜNER M., Tokat U. M., Chatzistamou I., Ersan P. G., et al.
Nature Communications
, cilt.14, sa.1, 2023 (SCI-Expanded, Scopus)
2023
202332. Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab
YILDIRIM H. Ç., KUŞ F., GÜVEN D. C., Karaca E., KAYGUSUZ Y., DİZDAR Ö., et al.
Journal of Immunotherapy and Precision Oncology
, cilt.6, sa.4, ss.170-176, 2023 (Scopus)
2023
202333. Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia
AKTAŞ B. Y., ATA E. B., ÇEŞMECİ E., ÇAKIR İ. Y., Coşkunpınar M., TAHILLIOĞLU Y., et al.
Current Oncology
, cilt.30, sa.11, ss.9689-9700, 2023 (SCI-Expanded, Scopus)
2023
202334. Molecularly imprinted electrochemical sensor for the selective and sensitive determination of octreotide in cancer patient plasma sample
Ozkan E., Ozcelikay G., Gök Topak E. D., NEMUTLU E., ÖZKAN S. A., DİZDAR Ö., et al.
Talanta
, cilt.263, 2023 (SCI-Expanded, Scopus)
2023
202335. Role of sarcopenia on survival and treatment-related toxicity in head and neck cancer: a narrative review of current evidence and future perspectives
ERUL E., GÜVEN D. C., ONUR M. R., YAZICI G., AKSOY S.
European Archives of Oto-Rhino-Laryngology
, cilt.280, sa.8, ss.3541-3556, 2023 (SCI-Expanded, Scopus)
2023
202336. Comparison of PD-L1 and VISTA expression status in primary and recurrent/refractory tissue after (chemo)radiotherapy in head and neck cancer
Şener G. Y., SÜTCÜOĞLU O., ÖĞÜT B., GÜVEN D. C., KAVUNCUOĞLU A., ÖZDEMİR N., et al.
Strahlentherapie und Onkologie
, cilt.199, sa.8, ss.761-772, 2023 (SCI-Expanded, Scopus)
2023
202337. GLIM criteria as a valid tool for nutrition assessment and mortality prediction in treatment-naïve patients with cancer
BALCI C., Tufan G., Özdemir N., AKSOY S., Öksüzoğlu Ö. B., ZENGİN N., et al.
Nutrition in Clinical Practice
, cilt.38, sa.4, ss.798-806, 2023 (SCI-Expanded, Scopus)
2023
202338. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors
GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., et al.
Anti-Cancer Drugs
, cilt.34, sa.6, ss.783-790, 2023 (SCI-Expanded, Scopus)
2023
202339. The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study
GÜVEN D. C., Yekeduz E., Erul E., YAZGAN S. C., ŞAHİN T. K., KARATAŞ G., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
, cilt.149, sa.7, ss.3599-3606, 2023 (SCI-Expanded, Scopus)
2023
202340. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
André F., Hee Park Y., Kim S., Takano T., Im S., Borges G., et al.
The Lancet
, cilt.401, sa.10390, ss.1773-1785, 2023 (SCI-Expanded, Scopus)
2023
202341. Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort
AKYILDIZ A., GÜVEN D. C., YILDIRIM H. Ç., Ismayilov R., YILMAZ F., Tatar O. D., et al.
Medicine (United States)
, cilt.102, sa.18, 2023 (SCI-Expanded, Scopus)
2023
202342. Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification
Saatci O., Akbulut O., Cetin M., Sikirzhytski V., ÜNER M., LENGERLİ D., et al.
Cell Death and Differentiation
, cilt.30, sa.5, ss.1305-1319, 2023 (SCI-Expanded, Scopus)
2023
202343. The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma
GÜVEN D. C., ERUL E., YILMAZ F., YAŞAR S., YILDIRIM H. Ç., ERCAN F., et al.
European Archives of Oto-Rhino-Laryngology
, cilt.280, sa.5, ss.2471-2478, 2023 (SCI-Expanded, Scopus)
2023
202344. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
Kahraman S., ERUL E., Seyyar M., GÜMÜŞAY Ö., Bayram E., Demirel B. C., et al.
Future oncology (London, England)
, cilt.19, sa.10, ss.727-736, 2023 (SCI-Expanded, Scopus)
2023
202345. Post-induction lymph node delineation in nasopharyngeal cancer: A single-center experience.
Sari S., YİĞİT E., YAZICI G., GÜLLÜ İ. H., AKSOY S., ÖZYİĞİT G., et al.
Head & neck
, cilt.45, sa.3, ss.612-619, 2023 (SCI-Expanded, Scopus)
2023
202346. Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group
DOĞAN İ., AKSOY S., Cakar B., BAŞARAN G., Ercelep O., Molinas Mandel N., et al.
Cancers
, cilt.15, sa.6, 2023 (SCI-Expanded, Scopus)
2023
202347. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy
GÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., et al.
INTERNATIONAL JOURNAL OF CANCER
, cilt.152, ss.679-685, 2023 (SCI-Expanded, Scopus)
2023
202348. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
Karacin C., Oksuzoglu B., Demirci A., KESKİNKILIÇ M., Baytemür N. K., Yılmaz F., et al.
BMC cancer
, cilt.23, sa.1, ss.136, 2023 (SCI-Expanded, Scopus)
2023
202349. Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer
YILDIRIM H. Ç., ÜNER M., Yildiran Özmen T., Chalabiyev E., GÜVEN D. C., KUŞ F., et al.
Journal of Oncological Science
, cilt.9, sa.1, ss.33-37, 2023 (Scopus, TRDizin)
2023
202350. Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment
Guven D. C., YILDIRIM H. Ç., KUŞ F., Erul E., KERTMEN N., DİZDAR Ö., et al.
Expert Review of Anticancer Therapy
, cilt.23, sa.10, ss.1049-1059, 2023 (SCI-Expanded, Scopus)
2023
202351. Evaluation of sarcopenia as a prognostic biomarker in locally advanced head and neck squamous cell carcinoma
ERUL E., Guven D. C., ÖZBAY Y., ALTUNBULAK A. Y., KAHVECİOĞLU A., ERCAN F., et al.
Biomarkers in medicine
, cilt.17, sa.2, ss.87-99, 2023 (SCI-Expanded, Scopus)
2022
202252. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
GÜVEN D. C., ŞAHİN T. K., ERUL E., Rizzo A., Ricci A. D., AKSOY S., et al.
Frontiers in Molecular Biosciences
, cilt.9, 2022 (SCI-Expanded, Scopus)
2022
202253. Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study
YILDIRIM H. Ç., MUTLU E., Chalabiyev E., Ozen M., KESKİNKILIÇ M., ÖN S., et al.
BREAST
, cilt.66, ss.85-88, 2022 (SCI-Expanded, Scopus)
2022
202254. Infectious complications of cyclin-dependent kinases 4 and 6 inhibitors in patients with hormone-receptor-positive metastatic breast cancer: a systematic review and meta-analysis
BAŞ O., Erul E., GÜVEN D. C., AKSOY S.
SUPPORTIVE CARE IN CANCER
, cilt.30, sa.11, ss.9071-9078, 2022 (SCI-Expanded, Scopus)
2022
202255. Phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer (mBC): KEYNOTE-B49
Schmid P., Sohn J. H., Jerez Gilarranz Y., Gonzalez-Cortijo L., Sonnenblick A., Sabanathan D., et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
, cilt.18, ss.233-234, 2022 (SCI-Expanded, Scopus)
2022
202256. The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges
GÜVEN D. C., ŞAHİN T. K., Rizzo A., Ricci A. D., AKSOY S., ŞAHİN K.
APPLIED SCIENCES-BASEL
, cilt.12, sa.20, 2022 (SCI-Expanded, Scopus)
2022
202257. Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease
YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.
JOURNAL OF CLINICAL MEDICINE
, cilt.11, sa.17, 2022 (SCI-Expanded, Scopus)
2022
202258. The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy
GÜVEN D. C., ŞAHİN T. K., Erul E., ÇAKIR İ. Y., ÜÇGÜL E., YILDIRIM H. Ç., et al.
JOURNAL OF CLINICAL MEDICINE
, cilt.11, sa.15, 2022 (SCI-Expanded, Scopus)
2022
202259. Optimization and normalization strategies for long term untargeted HILIC-LC-qTOF-MS based metabolomics analysis: Early diagnosis of breast cancer
REÇBER T., NEMUTLU E., Beksac K., CENNET Ö., Kaynaroglu V., AKSOY S., et al.
MICROCHEMICAL JOURNAL
, cilt.179, 2022 (SCI-Expanded, Scopus)
2022
202260. The effects of systemic aromatase inhibitors on meibomian glands and corneal structure
Agin A., KOCABEYOĞLU S., Gencoglu A. Y., AKSOY S., KARAKAYA KARABULUT J., Irkec M.
EYE
, cilt.36, sa.6, ss.1185-1193, 2022 (SCI-Expanded, Scopus)
2022
202261. The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis
GÜVEN D. C., ŞAHİN T. K., Erul E., KILIÇKAP S., Gambichler T., AKSOY S.
CANCERS
, cilt.14, sa.11, 2022 (SCI-Expanded, Scopus)
2022
202262. The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trials
GÜVEN D. C., Stephen B., ŞAHİN T. K., ÇAKIR İ. Y., Erul E., AKSOY S.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
, cilt.174, 2022 (SCI-Expanded, Scopus)
2022
202263. The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy
GÜVEN D. C., KAVGACI G., AKTEPE O. H., YILDIRIM H. H., ŞAHİN T. K., AKSOY S., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.28, sa.4, ss.785-793, 2022 (SCI-Expanded, Scopus)
2022
202264. Comparison of Clinical and Pathological Factors Affecting Early and Late Recurrences in Patients with Operable Breast Cancer
YEKEDÜZ E., DİZDAR Ö., KERTMEN N., AKSOY S.
JOURNAL OF CLINICAL MEDICINE
, cilt.11, sa.9, 2022 (SCI-Expanded, Scopus)
2022
202265. The Comparative Frequency of Breast Cancer-Related Lymphedema Determined by Bioimpedance Spectroscopy and Circumferential Measurements
Borman P., Yaman A., Dogan L., Donmez A., KOYUNCU E. G., BALCAN A., et al.
EUROPEAN JOURNAL OF BREAST HEALTH
, cilt.18, sa.2, ss.148-154, 2022 (ESCI, Scopus, TRDizin)
2022
202266. Liquid biopsy markers for early diagnosis of brain metastasis patients with breast cancer by metabolomics
Ozer O., NEMUTLU E., REÇBER T., Eylem C. C., AKTAŞ B. Y., KIR S., et al.
EUROPEAN JOURNAL OF MASS SPECTROMETRY
, cilt.28, sa.1-2, ss.56-64, 2022 (SCI-Expanded, Scopus)
2022
202267. HER2-low breast cancer could be associated with an increased risk of brain metastasis
GÜVEN D. C., KAYA M. B., Fedai B., ÖZDEN M., YILDIRIM H. Ç., KÖSEMEHMETOĞLU K., et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
, cilt.27, sa.2, ss.332-339, 2022 (SCI-Expanded, Scopus)
2022
202268. Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience
Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., TABAN H., et al.
FUTURE ONCOLOGY
, cilt.18, ss.323-331, 2022 (SCI-Expanded, Scopus)
2022
202269. The Impact of Hybrid Capture-Based Comprehensive Genomic Profiling on Treatment Strategies in Patients with Solid Tumors
Dişel U., Köse F., Bilici A., ÖZGÜROĞLU M., Sağlam S., ŞEKER M., et al.
Journal of Oncological Science
, cilt.8, sa.2, ss.87-93, 2022 (Scopus, TRDizin)
2022
202270. Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy
YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
, cilt.6, sa.1, ss.59-63, 2022 (ESCI, TRDizin)
2022
202271. Liquid biopsy: Novel perspectives on the importance and spectrum of PIK3CA, PTEN and RET mutations in solid tumors
Sahin I., Saat H., AKSOY S., DİZDAR Ö., Erdem H. B., Bahsi T.
MOLECULAR AND CLINICAL ONCOLOGY
, cilt.16, sa.1, 2022 (ESCI, Scopus)
2022
202272. The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study
GÜVEN D. C., YILDIRIM H. Ç., ERUL E., ŞAHİN T. K., ÇAKIR İ. Y., AKTEPE O. H., et al.
TURKISH JOURNAL OF MEDICAL SCIENCES
, cilt.52, sa.5, ss.1551-1558, 2022 (SCI-Expanded, Scopus, TRDizin)
2022
202273. p New Perspectives on the Recurrent BRCA Mutations and Clinical Variability
Sahin I., Saat H., AKSOY S.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.32, sa.1, ss.44-49, 2022 (SCI-Expanded, Scopus, TRDizin)
2022
202274. 18F FDG PET/CT after Neoadjuvant Chemotherapy and Pathological Responses are Predictive Factors for Disease-Free Survival and Overall Survival in Patients with Locally Advanced Breast Cancer: A Prospective Study
Kupik O., TUNCEL M., AKSOY S., Kiratli P. O., GÜLSÜN AKPINAR M., Altundag K., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.32, sa.3, ss.150-158, 2022 (SCI-Expanded, Scopus)
2021
202175. Upper limb sensory evaluations and ultrasonographic skin measurements in breast cancer-related lymphedema receiving complex decongestive physiotherapy
BARAN E., ÖZÇAKAR L., ÖZGÜL S., AKSOY S., AKBAYRAK T.
SUPPORTIVE CARE IN CANCER
, cilt.29, sa.11, ss.6545-6553, 2021 (SCI-Expanded, Scopus)
2021
202176. Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality
GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., Incesu F. G. G., TAHILLIOĞLU Y., et al.
BMJ SUPPORTIVE & PALLIATIVE CARE
, 2021 (SCI-Expanded, Scopus)
2021
202177. Clinical course and management of pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency: a new case and literature review
Oguz S. H., ÜNLÜTÜRK U., AKSOY S., Erbas T.
IMMUNOTHERAPY
, cilt.13, sa.14, ss.1157-1164, 2021 (SCI-Expanded, Scopus)
2021
202178. Sarcopenia and anthracycline cardiotoxicity in patients with cancer
BAŞ O., ERDEMİR A. G., ONUR M. R., ÖZER N., ŞENER Y. Z., AKSU S., et al.
BMJ SUPPORTIVE & PALLIATIVE CARE
, 2021 (SCI-Expanded, Scopus)
2021
202179. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors
GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., et al.
BIOMARKERS IN MEDICINE
, cilt.15, sa.13, ss.1123-1130, 2021 (SCI-Expanded, Scopus)
2021
202180. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy
GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al.
SUPPORTIVE CARE IN CANCER
, cilt.29, sa.9, ss.5417-5423, 2021 (SCI-Expanded, Scopus)
2021
202181. Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES
Im Y., KARABULUT B., Lee K. S., Park B., Adhav A., Cinkir H. Y., et al.
BREAST CANCER RESEARCH AND TREATMENT
, cilt.188, sa.1, ss.77-89, 2021 (SCI-Expanded, Scopus)
2021
202182. Radiation Recall Dermatitis in Patients Treated With Immune Checkpoint Inhibitors: A Case Report and Literature Review
Yigit E., GÜVEN D. C., AKSOY S., YAZICI G.
CUREUS
, cilt.13, sa.6, 2021 (ESCI)
2021
202183. THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY
GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., AKSUN M. S., KAVGACI G., Cebrayilov C., et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION
, cilt.36, 2021 (SCI-Expanded, Scopus)
2021
202184. Adjuvant treatment with paclitaxel plus trastuzumab for node negative human epidermal growth factor receptor 2-positive breast cancer: Real life experience
Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., Olgun P., et al.
CANCER RESEARCH
, cilt.81, sa.4, 2021 (SCI-Expanded, Scopus)
2014
201485. Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen
ŞENDUR M. A. N., Ozdemir N., Ozatli T., Yazici O., AKSOY S., Ekinci A. S., et al.
MEDICAL ONCOLOGY
, cilt.31, sa.9, 2014 (SCI-Expanded, Scopus)
1
186. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study
BİLİCİ A., ÖLMEZ Ö. F., Kaplan M. A., Oksuzoglu B., Sezer A., Karadurmus N., et al.
Acta Oncologica
, cilt.62, sa.4, ss.381-390, 1 (SCI-Expanded, Scopus)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
2024
20241. Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR plus ) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC study
Pernas S., Hinojo C., Pascual J., AKSOY S., Clack G., McIntosh S.
Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri)
2024
20242. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: A retrospective multi-center study by the Turkish Oncology Group (TOG).
Akyildiz A., Guven D. C., Koksal B., Karaoglan B. B., Salim D. K., Sutcuoglu O., et al.
Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri)
2024
20243. Reirradiation with Stereotactic Ablative Radiotherapy in Recurrent Nasopharyngeal Carcinoma
Yilmaz M. T., YİĞİT E., KAHVECİOĞLU A., YEDEKÇİ F. Y., YÜCE SARI S., CENGİZ M., et al.
9th International Congress on Innovative Approaches in Head and Neck Oncology (ICHNO), Barcelona, İspanya, 21 - 23 Mart 2024, (Özet Bildiri)
2024
20244. Reirradiation With Stereotactic Ablative Radiotherapy In Recurrent Head And Neck Cancers
YİĞİT E., Yilmaz M. T., KAHVECİOĞLU A., YEDEKÇİ F. Y., YÜCE SARI S., CENGİZ M., et al.
9th International Congress on Innovative Approaches in Head and Neck Oncology (ICHNO), Barcelona, İspanya, 21 - 23 Mart 2024, (Özet Bildiri)
2021
20215. Overcoming chemotherapy resistance in triple negative breast cancer via targeting lysyl oxidase (LOX)
Saatçi Ö., Akbulut Ö., Rezaeain A., Banister C., Sikirzhytski V., AKSOY S., et al.
AACR Virtual Special Conference, Virtual, Amerika Birleşik Devletleri, 11 - 12 Ocak 2021, cilt.81, (Özet Bildiri)
2019
20196. Detection of brain metastasis by metabolomics methods in metastatic breast cancer patients.
Özer Ö., NEMUTLU E., Eylem C. C., KIR S., REÇBER T., Aktas B. Y., et al.
2019 ASCO Annual Meeting, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2019, cilt.37, ss.12572, (Tam Metin Bildiri)
2019
20197. The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.
Cem O., Sedef A. M., Kose F., Oymak E., Guler O. C., Sumbul A. T., et al.
ASCO-SITC Clinical Immuno-Oncology Symposium, San-Francisco, Kostarika, 28 Şubat - 02 Mart 2019, cilt.37, (Özet Bildiri)
2019
20198. The outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.
Yildirim B., Cem O., Kose F., Oymak E., Sedef A. M., Besen A. A., et al.
ASCO-SITC Clinical Immuno-Oncology Symposium, San-Francisco, Kostarika, 28 Şubat - 02 Mart 2019, cilt.37, (Özet Bildiri)
2018
20189. KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma
Siu L. L., Licitra L., Tao Y. G., Yen C., Rischin D., Waldron J., et al.
Annual Meeting of the American-Association-for-Cancer-Research (AACR), Illinois, Amerika Birleşik Devletleri, 14 - 18 Nisan 2018, cilt.78, (Özet Bildiri)
2018
201810. Trace-Level Determination of 2-Amino Adipic Acid by LC-ESI-MS/MS for Early Diagnosis of Breast Cancer
REÇBER T., AKSOY S., NEMUTLU E., KIR S.
International Trace Analysis Congress, 20 - 23 Haziran 2018, (Özet Bildiri)
2018
201811. Mass Spectrometry Based Targeted and Untargeted Metabolomic Analysis for Early Diagnosis of Breast Cancer Using LC-ESI-qTOF-MS and LC-ESI-MS/MS
REÇBER T., AKSOY S., BEKSAÇ K., CENNET Ö., KAYNAROĞLU Z. V., NEMUTLU E., et al.
8TH 8th BLACK SEA BASIN CONFERENCE ON ANALYTICAL CHEMISTRY, 9 - 11 Mayıs 2018, (Özet Bildiri)
2018
201812. Adjuvan Yoğunluk Ayarlı Radyoterapi Uygulanan Baş-Boyun Kanserli Olgularda Tedavi Sonuçlarımız.
YÜCE SARI S., CENGİZ M., YAZICI G., ELMALI DOĞAN A., BEDÜK Ç. S., GÜLLÜ İ. H., et al.
13.Ulusal Radyasyon Onkolojisi Kongresi, Türkiye, 27 Nisan - 01 Mayıs 2018, (Tam Metin Bildiri)
2018
201813. Baş-Boyun Melanomlarında Radyoterapi Sonuçlarımız
YÜCE SARI S., YAZICI G., CENGİZ M., YILMAZ M. T., AKSOY S., GÜLLÜ İ. H., et al.
13. ULUSAL RADYASYON ONKOLOJİSİ KONGRESİ, Türkiye, 27 Nisan - 01 Mayıs 2018, (Tam Metin Bildiri)
2018
201814. Metastatik NUT Midline Karsinomunda İmmünoterapi ve Reirradyasyon: Vaka Sunumu.
ELMALI DOĞAN A., YILMAZ M. T., AKSOY S., YÜCE SARI S., ÖZYİĞİT G., YAZICI G.
13.Ulusal Radyasyon Onkolojisi Kongresi, Türkiye, 27 Nisan - 01 Mayıs 2018, (Tam Metin Bildiri)
2018
201815. GERİATRİK POPÜLASYONDAKİ YENİ TANIONKOLOJİK VAKALARDA MALNUTRİSYON VESARKOPENİ SIKLIĞI: ÇOK MERKEZLİ-KESİTSELÇALIŞMA
BALCI C., Tufan G., ÖZDEMİR N., AKSOY S., Öksüzoğlu Ö. B., ZENGİN N., et al.
11. Akademik Geriatri Kongresi, Antalya, Türkiye, 19 - 23 Nisan 2018, (Özet Bildiri)
2018
201816. High Prevelance of Malnutrition and Sarcopenia in Newly Diagnosed Cancer Patients in Turkey: Multicenter, Cross Sectional Study
BALCI C., Tufan G., ÖZDEMİR N., AKSOY S., Öksüzoğlu Ö. B., ZENGİN N., et al.
ASPEN 2018, Las-Vegas, Amerika Birleşik Devletleri, 22 - 25 Ocak 2018, (Özet Bildiri)
2017
201717. Bağışıklık sistemi baskılanmış hastalarda Microsporidia ve fırsatçı bağırsak parazitlerinin varlığının araştırılması
Kaya F., İNKAYA A. Ç., AKSOY S., ABBASOĞLU O., ERTENLİ A. İ., BÜYÜKAŞIK Y., et al.
4. Ulusal Klinik Mikrobiyoloji Kongresi, Türkiye, 8 - 12 Kasım 2017, (Özet Bildiri)
2017
201718. TRASTUZUMAB KARDİYOTOKSİSİTESİNİ İMMUNGLOBULİN /- STEROİD UYGULAMASI ÖNLEYEBİLİR Mİ?, TAVŞAN MODELİ HAYVAN DENEYİ
KERTMEN N., AKSOY S., ERMİŞ D. Y., KESKİN Ö., SOLAK M., ARIK Z., et al.
22. UKK, Türkiye, 19 - 23 Nisan 2017, (Özet Bildiri)
2016
201619. Role of glutamine for preventing oxaliplatin induced peripheralneuropathy GELUPO results of randomized open label phaseII tria
Yazıcı O., Titiz A., ÖZDEMİR N., AKSOY S., ŞENDUR M. A. N., Arlı B., et al.
ESMO 2016, 7 - 11 Ekim 2016, (Tam Metin Bildiri)
2016
201620. Impact of vitamin D3 replacement therapy on clinicaloutcomes and survival rates in patients with early stage breastcancer
YAZICI O., AKSOY S., ŞENDUR M. A. N., ÖZDEMİR N., ZENGİN N., ALTUNDAĞ M. K.
ESMO 2016, 7 - 11 Ekim 2016, (Tam Metin Bildiri)
2016
201621. Effect of body mass index in the outcome of stage I III triplenegative breast cancer
ŞENDUR M. A. N., AKSOY S., ÖZDEMİR N., Yazıcı O., ZENGİN N., ALTUNDAĞ M. K.
ESMO 2016, 7 - 11 Ekim 2016, (Tam Metin Bildiri)
2016
201622. Effect of using different antihypertensive drugs ondemographic and clinico pathological characteristics ofbreast cancer
ŞENDUR M. A. N., AKSOY S., ÖZDEMİR N., Yazıcı O., AKINCI M. B., ŞENER DEDE D., et al.
ESMO 2016, 7 - 11 Ekim 2016, (Tam Metin Bildiri)
2016
201623. Effect of polypharmacy on treatment preferences andoutcome in older breast cancer patients
ŞENDUR M. A. N., SILAY K., AKSOY S., Özbek S., ÖZDEMİR N., ALTUNDAĞ M. K.
ESMO 2016, 7 - 11 Ekim 2016, (Tam Metin Bildiri)
2016
201624. Effect of using different antidiabetic drugs on demographicand clinico pathological characteristics of breast cancer
ŞENDUR M. A. N., AKSOY S., Yazıcı O., ÖZDEMİR N., ŞENER DEDE D., AKINCI M. B., et al.
ESMO 2016, 7 - 11 Ekim 2016, (Tam Metin Bildiri)
2016
201625. Survival and Larynx Preservation Rates after Definitive Radiotherapy A Single Center Experience
CENGİZ M., YÜCE SARI S., GÜLTEKİN M., SÜSLÜ N., AKSOY S., KUŞCU O., et al.
ECHNO 2016, Budapest, Macaristan, 7 - 10 Eylül 2016, (Özet Bildiri)
2016
201626. Comparison of clinical outcomes in patents with early stage ER PR HER2 breast cancer patients with triple negatives
Erdem G. U., AKSOY S., ŞENDUR M. A. N., ÖZDEMİR N., Doğan M., ZENGİN N., et al.
2016 ASCO Annual Meeting, 29 Mayıs - 03 Haziran 2016, (Özet Bildiri)
2016
201627. The impact of the total size of lesions in multifocal multicentric breast cancer on survival
Karakaş Y., DİZDAR Ö., Akın S., ATEŞ Ö., ŞENDUR M. A. N., AKSOY S., et al.
2016 ASCO Annual Meeting, 29 Mayıs - 03 Haziran 2016, (Tam Metin Bildiri)
2016
201628. Clinicopathologic characteristics of patients with recurrent or metastatic synovial sarcoma
ATEŞ Ö., AKSOY S., YETER H. H., Akın S., KERTMEN N., DİZDAR Ö., et al.
2016 ASCO Annual Meeting, 29 Mayıs - 03 Haziran 2016, (Tam Metin Bildiri)
2016
201629. Intravenous ferric carboxymaltose treatment in cancer patients
ASLAN A., TAŞDEMİR V., KERTMEN N., DİZDAR Ö., AKSOY S.
2016 ASCO Annual Meeting, 29 Mayıs - 03 Haziran 2016, (Tam Metin Bildiri)
2016
201630. Modified docetaxel cisplatin and fluorouracil therapy as a first line treatment for patients with recurrent metastatic squamous cell carcinoma of the head and neck cancer a retrospective study
DEMİRCİ N., AKSOY S., ÖZDEMİR N., Babacan T., ERDEM G. U., BOZKAYA Y., et al.
2016 ASCO Annual Meeting, 29 Mayıs - 03 Haziran 2016, (Tam Metin Bildiri)
2015
201531. Serological Detection of Strongyloides strecoralis infection in immunosupressed patients Hacettepe Experience
Kaya F., ERTENLİ A. İ., İNKAYA A. Ç., ABBASOĞLU O., AKSOY S., AKYÖN YILMAZ Y., et al.
Acta Microbiologica Helenica (9th Balkan Congress of Microbiology), 22 - 24 Ekim 2015
2015
201532. SEROLOGICAL DETECTION OF STRONGYLOIDES STERCORALIS INFECTION IN IMMUNOSUPRESSED PATIENTS: HACETTEPE EXPERIENCE
DEMİREL KAYA F., ERTENLİ A. İ., İNKAYA A. Ç., ABBASOĞLU O., AKSOY S., AKYÖN YILMAZ Y., et al.
9TH BALKAN CONGRESS OF MICROBIOLOGY, SELANİK, Yunanistan, 22 - 24 Ekim 2015, (Özet Bildiri)
2015
201533. Kadri Altundag Taner Babacan Orhan Efe Ahmet S Hasırcı Fatih Demirci Hakan Buyukhatıpoglu Ozan Balakan Furkan Saim Sarıcı Neyran Kertmen Ece Esin Serkan Akin Ozturk Ates Sercan Aksoy Ali R Sever
ALTUNDAĞ M. K., Babacan T., EFE O., HASIRCI A. S., DEMİRCİ F., BUYUKHATİPOGLU H., et al.
2015 ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri)
2015
201534. Brain specific progression free survival bsPFS according to breast cancer subtypes in patients with brain metastases
ARSLAN Ç., YAZICI O., AKSOY S., ALTUNDAĞ M. K.
2015 ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri)
2015
201535. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer
Ateş Ö., Babacan T., SARICI F., KERTMEN N., CENOLİ A., Akın S., et al.
ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri)
2015
201536. Study of the impact of Charlson comorbidity index on the efficacy of aromatase inhibitors in patients with hormone receptor positive postmenopausal breast cancer
ŞENDUR M. A. N., AKSOY S., SILAY K., AKINCI M. B., ÖZDEMİR N., YAZICI O., et al.
2015 ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri)
2015
201537. Neuroendocrine breast cancer A single center experience
TAŞDEMİR V., Kertmen N., CENOLİ A., KESKİN Ö., KARAKAS Y., Diker Ö., et al.
2015 ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri)
2015
201538. Tumor locations significantly affect disease free survival and overall survival
BUYUKHATİPOGLU H., Babacan T., KERTMEN N., Ateş Ö., AKTAŞ G., ŞENDUR M. A. N., et al.
2015 ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri)
2015
201539. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.
Altundag K., Babacan T., Efe O., Hasirci A. S., Demirci F., Buyukhatipoglu H., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
2015
201540. The role of the gastrectomy on survival in metastatic gastric cancer patients: A multicenter study of Anatolian Society of Medical Oncology (ASMO)
Yazici O., Ozdemir N., Duran A. O., Menekse S., Sendur M. A. N., Karaca H., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
2014
201441. Efficacy of adjuvant tamoxifen in hormone receptor-positive premenopausal breast cancer patients according to the body mass index
Altundag K., Sendur M. A. N., AKSOY S., BABACAN T., Ozisik Y.
37th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 9 - 13 Aralık 2014, cilt.75, (Özet Bildiri)
2014
201442. Comparison of three different induction regimen in nasopharyngeal cancer: CF versus DC versus DCF.
Kertmen N., Aksoy S., Cengiz M., Yazici G., Keskin O., Babacan T., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri)
2014
201443. Which sequence prevents the heart from trastuzumab and anthracycline toxicity: Electron microscopy study in rats
Aksoy S., Kertmen N., ÜNER A., Sargon M., Ozkayar O., Keskin O., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri)
2014
201444. Effect of body mass index on metastatic pattern in early breast cancer patients.
Yazici O., Aksoy S., Sendur M. A. N., Ozdemir N., Zengin N., Altundag K.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri)
2014
201445. Comparison of long-term cardiac effects of 9-and 52-week trastuzumab in HER2-positive early breast cancer.
Sendur M. A. N., Aksoy S., Ozdemir N., Yorgun H., Yilmaz F. M., Yazici O., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri)
2014
201446. Predictors of outcome in patients with advanced nonseminamatous germ cell testicular tumors.
Yetisyigit T., Babacan N., Urun Y., Seber S., Arpaci E., Clhan S., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri)
2013
201347. Inflammatory markers in metastatic breast cancer.
Sahin U., Petekkaya H., Gecmez G., Babacan T., Roach E. C., Sarici S. F., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2013
201348. Metformin in diabetic pancreatic cancer patients: Benefit or not-Multicenter experience.
Esbah O., Oksuzoglu B., Eren T., Helvaci K., Guler T., Duran A. O., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2013
201349. Retrospective analysis of 178 patients with stage I rectum cancer.
Cihan S., Ozdemir N., Urakci Z., Kucukoner M., Dane F., Yazilitas D., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2013
201350. Outcomes of patients with HER2-negative breast cancer with central nervous system metastasis treated with capecitabine.
Altundag K., Aksoy S., Sendur M. A. N., Guler E. N., Gullu I. H., Ozisik Y. Y.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2013
201351. Association of the neutrophil to lymphocyte ratio with survival patients with in metastatic breast cancer.
Unlu O., Aygun S., Petekkaya H., Gecmez G., Roach E. C., Babacan T., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2013
201352. Arrhythmias during and after zoledronic acid infusion patients with bone metastasis.
Yazici O., Aksoy S., Ucar O., Ozdemir N., Demir M., Sendur M. A. N., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2013
201353. Retrospective review of modified dose docetaxel, cisplatin, and 5-flourouracil (DCF) for the treatment of first-line metastatic gastric carcinomas.
Ozdemir N., Aksoy S., Eren T., Abali H., Oksuzoglu O. B., Zengin N.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2013
201354. Comparison of the efficacy of adjuvant letrozole and anastrozole in hormone-receptor positive postmenopausal breast cancer patients.
Sendur M. A. N., Aksoy S., Altundag K.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2013
201355. Clinicopathologic characteristics of pure papillary breast carcinoma
Turkoz F. P., Solak M., Keskin O., Arik Z., Arslan C., Kertmen N., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2013
201356. Inflammatory markers in early-stage breast cancer.
Petekkaya H., Aksoy S., Gecmez G., Kulahcioglu E., Okoh A. K., Isler D. C., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2013
201357. Demographic and clinicopathologic characteristics in patients with invasive breast cancer receiving metformin.
Aksoy S., Sendur M. A. N., Altundag K.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2013
201358. The number of metastatic lymph node in N3M0 breast cancer and influence on survival.
Solak M., Turkoz F. P., Keskin O., Petekkaya H., Sarici S. F., Babacan T., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2013
201359. Labeling of Faces in Personal Photo Albums
ŞENER T. E., Yucel U. C., AKSOY S., Buyukgebiz I., Uzun B., DUYGULU ŞAHİN P.
21st Signal Processing and Communications Applications Conference (SIU), CYPRUS, 24 - 26 Nisan 2013, (Tam Metin Bildiri)
2012
201260. Administration of contrast media just before the cisplatin-based chemotherapy increases the cisplatin-induced nephrotoxicity.
Sendur M. A. N., Aksoy S., Yaman S., Kos F. T., Arik Z., Civelek B., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri)
2012
201261. Retrospective analysis of octagenarian breast cancer patients: Multicenter retrospective study.
Dizdar O., Arslan C., Eren T., Yalcin S., Kucukoztas N., Aksoy S., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri)
2012
201262. Variations of the ER, PR, and HER2 expression status according to operation day in breast cancer patients.
Arik Z., Aksoy S., Sendur M. A. N., Yaman S., Altundag K.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri)
2012
201263. Does total breastfeeding time influence the clinicopathologic characteristics and prognosis in breast cancer patients?
Yaman S., Aksoy S., Sendur M. A. N., Arik Z., Ozdemir N., Zengin N., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri)
2012
201264. Demographic and clinicopathologic characteristics of breast cancer patients with history of oral alendronate use
Aksoy S., Sendur M. A. N., Yaman S., Arik Z., Ozdemir N., Zengin N., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri)
2006
200665. Cigarette smoking and risk of pulmonary metastasis from breast cancer
Aksoy S., Altundag K., Ozisik Y., Guler N., Gullu I., Kars A., et al.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.102, (Özet Bildiri)
2006
200666. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma
Kilickap S., Yavuz B., Aksoy S., Sahiner L., Harputluoglu H., Dincer M., et al.
30th Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.202, (Özet Bildiri)
Kitaplar
2017
20171. Systemic Therapies in the Managementof Testicular Cancers
ŞENDUR M. A. N., AKSOY S.
Principles and Practice of UrooncologyRadiotherapy, Surgery and SystemicTherapy, Ozyigit, Gokhan, Selek, Ugur (Eds.), Editör, Springer, 2017
2017
20172. Targeted Therapies and Immunotherapy in Bladder Cancer
ŞENDUR M. A. N., AKSOY S.
Principles and Practice of UrooncologyRadiotherapy, Surgery and SystemicTherapy, Ozyigit, Gokhan, Selek, Ugur (Eds.), Editör, Springer, ss.141-152, 2017
2016
20163. Kanser ve Kalp Yetmezliği
ŞENDUR M. A. N., AKSOY S.
Kalp Yetmezliği Cep Kitabı, Prof. Dr. Ali Oto, Prof. Dr. Barış Kaya, Prof Dr. Kudret Aytemir, Editör, Erkem Tıbbi Yayıncılık, 2016
2016
20164. Systemic Therapies in Malignant Pleural Mesothelioma
Yazıcı O., AKSOY S.
Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies, Gokhan Ozyigit, Ugur Selek, Erkan Topkan , Editör, Springer, ss.469-481, 2016
2015
20155. Current Systemic Therapy Options for Head and Neck Cancer
ŞENDUR M. A. N., AKSOY S.
Radiation Therapy for Head and Neck CancersA Case Based Review, Murat Beyzade, Gökhan Ozyigit, ugur Selek, Editör, Springer, 2015
Desteklenen Projeler
2014 - 2020
2014 - 2020Hemşireler İçin Temel Palyatif Bakım Kursu
Yükseköğretim Kurumları Destekli Proje , BAP Diğer
AKSOY S. (Yürütücü)